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Abstract
Background: The impact of flat-line funding in the global scale up of antiretroviral therapy (ART) for HIV-infected patients in
Africa has not yet been well described.
Methods: We evaluated ART-eligible patients and patients starting ART at a prototypical scale up ART clinic in Mbarara,
Uganda between April 1, 2009 and May 14, 2010 where four stakeholders sponsor treatment – two PEPFAR implementing
organizations, the Ugandan Ministry of Health – Global Fund (MOH-GF) and a private foundation named the Family
Treatment Fund (FTF). We assessed temporal trends in the number of eligible patients, the number starting ART and
tabulated the distribution of the stakeholders supporting ART initiation by month and quartile of time during this interval.
We used survival analyses to assess changes in the rate of ART initiation over calendar time.
Findings: A total of 1309 patients who were eligible for ART made visits over the 14 month period of the study and of these
819 started ART. The median number of ART eligible patients each month was 88 (IQR: 74 to 115). By quartile of calendar
time, PEPFAR and MOH sponsored 290, 192, 180, and 49 ART initiations whereas the FTF started 1, 2, 1 and 104 patients
respectively. By May of 2010 (the last calendar month of observation) FTF sponsored 88% of all ART initiations. Becoming
eligible for ART in the 3
rd (HR=0.58, 95% 0.45–0.74) and 4
th quartiles (HR=0.49, 95% CI: 0.36–0.65) was associated with
delay in ART initiation compared to the first quartile in multivariable analyses.
Interpretation: During a period of flat line funding from multinational donors for ART programs, reductions in the number
of ART initiations by public programs (i.e., PEPFAR and MOH-GF) and delays in ART initiation became apparent at the a large
prototypical scale-up ART clinic in Uganda.
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Introduction
Although multinational HIV/AIDS treatment programs have
been one of greatest public health successes this century,
diminishing resource commitments by major donors have raised
uncertainty about the future of access to antiretroviral therapy
(ART) and the goal of universal access. To date, the United States
Congress has authorized $48 billion to combat HIV/AIDS,
tuberculosis and malaria via both bilateral programs, including the
President’s Emergency Plan for AIDS Relief (PEPFAR), and
contributions to the multilateral Global Fund to Fight AIDS,
Tuberculosis and Malaria through fiscal year 2013 and have
supported ART for nearly 3.7 million persons in resource limited
settings [1]. Despite concerns about the feasibility of implementing
life-long HIV therapy with limited health care infrastructure, the
scale-up of ART has been accompanied by rates of medication
adherence and viral suppression which exceeded expectations and
in many cases surpassed precedents established in North America
and Western Europe [2,3,4]. These clinical benefits have lead to
evidence of increases in population level life expectancy, reduced
rates of HIV/AIDS related orphans and mitigated the economic
impacts of HIV/AIDS on many developing countries [5,6].
Overall, despite the fact that early mortality [7] and losses to
follow-up are high [8], the effectiveness of the global ART roll out
is indisputable. These successes notwithstanding, funding at the
global level has been flat during 2009–2010 [9] and the United
States President’s 2011 Budget Request to Congress contains
6.7 billion in total global HIV funding which represents a 2.2%
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of anticipated needs at a time when less than 50% of persons with
immediate need for ART in Africa are accessing it [11–14].
To date, however, relatively little public data exists that provides
information on trends in the availability of slots for ART initiation
and the distribution of stakeholders who sponsor ART initiation in
this funding climate. The Immune Suppression Syndrome (ISS)
Clinic in Mbarara, Uganda is a prototypical ART clinic and is
uniquely situated to examine the relative contributions of different
funders supporting ART initiations because four different stake-
holders operate simultaneously in one location – two PEPFAR
partner organizations, the Ugandan Ministry of Health – Global
Fund and a private foundation (Family Treatment Fund; http://
familytreatmentfund.org). The clinic started its first patients on
ART in 2002, before large scale multilateral efforts had arrived,
using funding from FTF. In 2004–2005 the clinic grew rapidly
with rapid influx of PEPFAR and Global Fund support and the
FTF took on an ancillary role in providing ART for patients
during medication stock outs, supplying treatment for opportu-
nistic infections and training HIV-infected patients on household
income generation. We hypothesized that the recent limited
increases in funding for HIV programs would translate into
decreased availability of treatment slots sponsored by PEPFAR
programs and place a greater reliance on programs such as FTF.
Methods
Ethics Statement
The study was approved by the institutional review board of
University of California, San Francisco, the Mbarara University of
Science and Technology and the Uganda National Counsel of
Science and Technology. The ethics approvals for this study allow
for the analysis of de-identified clinic data already collected in the
course of routine care, therefore no specific written or verbal
consent was obtained.
The ISS Clinic serves the Mbarara District (population 1.1
million, 92% in rural areas) as well as portions of adjacent districts
and is a prototypical implementer of the ‘‘public health approach’’
to ART delivery which means that it serves a large number of
patients without the benefit of sophisticated monitoring (e.g.,
routine HIV RNA determination) nor subspecialty trained doctors
and with medications limited to ‘‘simplified and standardized’’
regimens in WHO guidelines [9]. As of May 14, 2010, over 18,094
patients have been seen at the ISS clinic. Four to six clinical and
medical officers staff up to 250 visits a day. From the ISS Clinic we
evaluated ART naı ¨ve adult patients with CD4-based indications
for ART initiation and who made a visit between April 1, 2009
and May 14, 2010. Demographic and clinical characteristics were
obtained from the clinic’s electronic medical record system.
The stakeholder (e.g., PEPFAR implementing partner, the
MOH or FTF) that sponsors ART for a new patient was
abstracted from clinical records. The ART number for each
patient is determined by the pharmacy staff who assigns an ‘‘ART
number’’ prior to ART initiation. The ART number is comprised
of a ‘‘prefix’’ that identifies the program sponsoring the ART (e.g.,
PEPFAR, MOH or FTF) as well as a ‘‘suffix’’ that uniquely
identifies the patient. Once assigned, the ART number is entered
into the pharmacy and clinical databases and is henceforth present
on the patient’s records. When the patient goes to the pharmacy to
pick up medications, the ART number is used to determine the
source for the prescription refill. Therefore, the ART number is a
reliable link to the ART program sponsoring medications for each
patient.
We calculated the number of patients starting ART each month
and quartile of calendar time among eligible patients. We also
tabulated the distribution of patients starting ART in each
calendar month and quartile of calendar time by the organization
providing funding. We used the Kaplan-Meier method to calculate
time from ART eligibility (as determined by first CD4 count ,
or=250 cells/cc
3) to ART initiation stratified by calendar time to
examine whether a later calendar time of eligibility was associated
with a delayed ART initiation. This survival analysis was restricted
to the patients who became eligible for the first time between April
1, 2009 and May 14, 2010 to avoid selecting patients with longer
eligibility times into the first quartile. Calendar time was
discretized into quartiles, and the effect of each quartile was
compared to the first quartile as an indicator variable. The log-
rank test was used to evaluate significance of observed differences.
We used a Cox proportional hazards model to estimate the effect
of calendar time (as partitioned in quartiles) on the rate of ART
initiation adjusting for three variables of a priori importance (age,
sex, and pre-therapy CD4 count). Pre-therapy CD4 levels were
discretized as per convention at 0–50 cells/cc
3, 51–100 cells/cc
3,
101–150 cells/cc
3 and 151–250 cells/cc
3.All analyses were
conducted in Stata v.10 (College Station, TX). The funders had
no role in the design, analysis or interpretation of the results.
Results
Between April 1, 2009 and May 14, 2010, 1309 patients made
visits who had indications to start ART by virtue of a CD4
determination ,250/cc
3 (as per Ugandan National Antiretroviral
Treatment Guidelines) [10]. As typical of HIV clinic populations
in East Africa, 61% of the patients were female and 39% male.
The median age was 36 year (IQR, 31–39). Median CD4+ T cell
value at the time of an indication was 110 cells/cc
3 (IQR: 39 to
175). Over 14 months, the median number of patients making
visits with ART indications each month was 88 (IQR: 74 to 115).
Overall the total number of patients starting ART over the last 14
months was 819. Of these 819, PEPFAR programs started 318
(39%) on ART, the MOH started 393 (48%) and FTF started 108
(13%).
Secular trends show large shifts in the stakeholder providing
therapy (Figure 1). Overall, the contribution of PEPFAR-
sponsored ART initiations fell markedly between April 1
st, 2009
and May 14
th, 2010. By quartile of calendar time, PEPFAR and
MOH sponsored 290, 192, 180, and 49 ART initiations whereas
the FTF started 1, 2, 1 and 104 patients respectively. When
examined by monthly fractions, the trends are more apparent
(Figure 2). At the beginning of the interval – in April of 2009 –
PEPFAR implementing partners accounted for 68/93 (73%) or
ART initiations. In October PEPFAR sponsored initiations
dropped rapidly to 10/39 (26%) and then continued to decline
subsequently. MOH sponsored ART initiations rose in number
when PEPFAR initiations declined in October 2009: while the
MOH started an average of 20 patients a month between April
2009 and October 2009, by November MOH initiations rose to
61/67 (92%) of all ART initiations. MOH maintained a high
proportion of starts until April and May of 2010 when MOH
sponsored ART initiations then fell to 5/75 (7%). Over this 14
month interval, FTF sponsored very few ART initiations until
February when FTF sponsored initiations grew to 7/57 (12%). In
March FTF sponsored 18/50 (36%) ART initiations; in April FTF
sponsored 45/51 (88%) initiations and at the time of the database
closure on May 14
th, FTF sponsored 21/24 (88%) initiations in
May.
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of 1309 patients who became eligible for the first time during the
interval between April 1, 2009 and May 14
th, 2010. The number
who became eligible in the first through fourth quartiles
respectively was: 168 (24%), 199 (29%), 156 (22%) and 174
(25%). The three month cumulative incidence of ART initiation in
Figure 1. The number of ART initiations each week by stakeholder from April 1, 2009 to May 10
th, 2010 at the ISS Clinic, Mbarara,
Uganda.
doi:10.1371/journal.pone.0014098.g001
Figure 2. The percentage of monthly ART initiations by stakeholder, ISS Clinic, Mbarara, Uganda. The total number starting per month
is shown across the top of the bars.
doi:10.1371/journal.pone.0014098.g002
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(95% CI: 57%–70%), 49% (42%–57%) and 47% (95% CI: 38%–
57%). The log-rank test for equality of survivor functions was
significant at p,0.001 (Figure 3). In a Cox model adjusting for
age, sex and baseline CD4 value, the rate of ART initiation in the
second quartile was 0.93 (95% CI: 0.74–1.18), in the third quartile
was 0.61 (95% CI: 0.47–0.80) and in the fourth quartile was 0.53
(95% CI: 0.39–0.73) when compared to the first quartile. Age and
sex were not significantly associated with the rate of ART
initiation, but a baseline CD4 value of 0–50 cells/cc
3 was
associated with an increased rate of ART initiation (HR=1.43,
95% CI: 1.12–1.83) compared to the reference group of baseline
CD4 from 150–250 cells/cc
3 (Table 1).
Discussion
We found diminishing ARV supply for new ART initiation by
large PEPFAR sources and an increasing reliance on FTF at a
prototypical HIV clinic in southwestern Uganda during a period
when ART-eligible patients continued to present to care. We also
found a nearly 50% decline in the rate of ART initiation for
patients who presented in the final quartile of calendar time (from
February to Mary 2010) as compared to the first quartile (April to
mid-June, 2009) that translates into a decrease in the 90 day
cumulative incidence of ART initiation from 71% to 47% or an
absolute difference of 24%. These delays in ART initiation at the
ISS Clinic during this period of time coincided with a rapid fall in
the number of slots available from PEPFAR in October of 2009 –
the time of the ‘‘PEPFAR Halt Memo’’ which is a widely
circulated document putatively from US CDC in Uganda
requesting implementing partners stop routine initiation of new
patients on ART [11]. Given fluctuations in the delivery of new
treatment slots from MOH, ART initiation at the ISS Clinic
during March to May 2010 was largely covered by a small
foundation – the Family Treatment Fund. With an average of 88
patients a month who present with indications for ART and the
fact that FTF is rapidly reaching capacity, access to ART for the
steady stream of eligible patients may continue to be less timely
and reliable in the foreseeable future without sustained coverage
from the major stakeholders.
These data support concerns raised in the popular press and by
advocacy groups that flat line funding will lead to a step backwards
in the fight against HIV/AIDS. Groups like Doctors without
Borders have made high profile lobbying efforts in the United
Figure 3. Time from eligibility for ART (as determined by Ugandan National ART Guidelines of a CD4 count less than or equal to
250 cells/mm
3) to initiation of ART. The denominator in this analysis is restricted to the subset of patients who became eligible for ART for the
first time between April 1, 2009 and May 14, 2010.
doi:10.1371/journal.pone.0014098.g003
Table 1. Cox proportional hazards model on the association
of calendar time of ART eligibility (as determined by CD4 level)
and rate of ART initiation, adjusting for age, sex and pre-therapy
CD4 value.
Factor
Hazard
ratio
95% Conf.
Interval P-value
Calendar time
Quartile 1 (Apr.1, 2009-Jul.15, 2009) ref
Quartile 2 (Jul.16, 2009-Nov.30, 2009) 0.93 0.74–1.18 0.57
Quartile 3 (Dec.1, 2009-Feb.15, 2010) 0.61 0.47–0.80 ,0.01
Quartile 4 (Feb.16, 2010-May 14, 2010) 0.53 0.39–0.73 ,0.01
Age 1.00 0.99–1.01 0.65
Sex 1.03 0.83–1.26 0.80
Pre-therapy (i.e., baseline) CD4 value
0–50 cells/mm
3 ref
51–100 cells/mm
3 1.18 0.81–1.55 0.65
101–150 cells/mm
3 1.05 0.79–1.41 0.45
151–250 cells/mm
3 1.43 1.21–1.83 ,0.01
doi:10.1371/journal.pone.0014098.t001
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initiation and have warned of the return of waiting lists [12].
Indeed, for those with CD4 levels of ,200 cells/cc
3, mortality in
Africa without ART reaches 30% by 1 year and therefore even
incremental delays in ART initiation are likely to lead to increases
in preventable HIV-related deaths. Multiple funders have, we
believe, relatively insulated the ISS Clinic from individual
stakeholder shortfalls. This is not the case in smaller clinics in
the community, where limited ART initiations by one stakeholder
are not so easily accommodated. The impact of PEPFAR funding
limitations on the number of and time to ART initiation in eligible
patients may be more pronounced at those sites.
While we observed dramatic shifts in funding source at a single
clinic, we recognize that the absolute level of funding at the global
or national level is not the only determinant of ART availability in
sub-Saharan Africa. Consistent ART supply requires procure-
ment, storage and delivery of medications [13]. At the recent 2010
International AIDS Society Conference in Vienna, a number of
global health leaders called for maximizing the availability of ART
through exploiting ‘‘efficiencies’’[14] in delivery of HIV/AIDS
care. Further research on maximizing efficiencies is necessary to
increase capacity to meet projected geometric increases in demand
in setting of linear increases in funding [13].
This study has several limitations. First, while we describe rapid
changes in treatment source concurrent with changes in funding
allocation we cannot exclude important unmeasured factors that
determine ART delivery. These factors may include the
mechanisms in the delivery of ART supplies, the pharmacy stock
available at the Ugandan national level among others. However,
our findings of a rapid decline in PEPFAR-supported ART
initiations in November 2009 coincides with a October 29, 2009
letter from CDC Uganda instructing PEPFAR implementing
partners to cease routine enrollment of new ART patients [12]
which supports a causal interpretation. A second limitation is that
the center which we studied has four simultaneous stake holding
organizations (e.g., two PEPFAR implementing partners, the
MOH and FTF). While this unusual arrangement limits the
generalizability of our findings to other ART sites in the region, it
provides a unique opportunity to examine trends across all
stakeholders and therefore act as a gauge of the ART availability
in the region. Based on anecdotal evidence, the restrictions in
ART initiations for in lower-level health centers surrounding the
Mbarara ISS Clinic in southwestern Uganda were more – not less
– severe.
In summary, these findings suggest that changes in the
multinational funding landscape had an impact on ART initiation
at the clinic level in Uganda. This effect occurred via a sudden
reduction in the number of new PEPFAR-funded ART treatment
initiations and a letter from US CDC instructing implementing
partners to stop enrolling new patients [12]. If these trends
continue, increased efficiency of care delivery may not be sufficient
to meet projected increases in demand for treatment. Couples,
friends and family already on ART may experience pressure to
share ART medications with loved ones who are ART eligible but
on waiting lists, leading to partial viral suppression, increased drug
resistance, and thereby impairing future ART treatment benefits
once additional resources become available. ART initiation
declines may also reverse favorable trends in HIV disease
prevention efforts that include reduction of stigma, rise in
acceptability of testing and penetration of public health messages
into society. Increasing commitments from both multilateral
donors and national governments in Africa will be required to
secure the achievements to date.
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